Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $789.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 19.37% year-over-year to $789.0 million in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 3.15% increase from a year earlier, with the FY2025 full-year figure at $899.4 million, up 21.15% from the prior year.
• Liabilities and Shareholders Equity declined to $789.0 million in Q1 2026 per VRDN's latest filing, from $899.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $899.4 million in Q4 2025 and bottomed at $169.8 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $577.1 million (2025), against an average of $530.9 million.
• Across the five-year window, Liabilities and Shareholders Equity declined 25.38% in 2023 and jumped 134.79% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $435.1 million in 2022, then rose by 12.72% to $490.4 million in 2023, then soared by 51.38% to $742.4 million in 2024, then climbed by 21.15% to $899.4 million in 2025, then fell by 12.27% to $789.0 million in 2026.
• Per Business Quant, the three latest VRDN Liabilities and Shareholders Equity figures stand at $789.0 million (Q1 2026), $899.4 million (Q4 2025), and $577.1 million (Q3 2025).